Clinical Report: Challenges in Disproportionality Analysis and Mitigation Approaches

Overview

This commentary discusses the complexities and pitfalls in disproportionality analysis (DPA), emphasizing the utility of the regression-adjusted gamma-Poisson shrinker (RGPS) in addressing confounding and masking effects.

Background

Disproportionality analysis is crucial in pharmacovigilance for identifying potential drug-event associations. However, analysts may encounter pitfalls that can lead to erroneous conclusions. Understanding and mitigating these challenges is essential for accurate signal detection.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• RGPS combines logistic regression with DPA's observed-to-expected framework to adjust for confounding variables.
• Masking can obscure true drug-event associations, which RGPS aims to unmask by including relevant non-target drugs in the analysis.
• Confounding can lead to misattribution of event risk, which RGPS addresses by conditioning on co-reported drugs.
• RGPS provides standardized regression coefficients (SRCs) to assess the contributions of drugs and covariates to expected counts.
• Higher values in RGPS measures indicate stronger evidence of disproportionality in drug-event reporting.

Clinical Implications

Awareness of the complexities involved in disproportionality analysis is essential to avoid misinterpretation of data.

Conclusion

This commentary highlights the importance of addressing pitfalls in disproportionality analysis through advanced methodologies.

Related Resources & Content

1. Fusaroli et al., Drug Safety, 2025 -- Challenges in Disproportionality Analysis
2. Drug Safety, 2020 -- Guidelines for Minimizing False-Positive Associations
3. Drug Safety, 2025 -- Amendment: Navigating and Avoiding the Challenges of Disproportionality Analysis
4. Drug Safety, 2025 -- Navigating the Challenges and Misinterpretations of Disproportionality Analysis
5. European Medicines Agency (EMA) -- Good pharmacovigilance practices (GVP)
6. UMC -- vigiMethods
7. Drug Safety — Strategies for Evaluating and Enhancing the Validity of Disproportionality Signals: A Meta-Research Analysis
8. Good pharmacovigilance practices (GVP) | European Medicines Agency (EMA)
9. vigiMethods | UMC
10. Quarterly persistence as a signal prioritization framework in FAERS: an analysis of the 2025 public-use releases | Naunyn-Schmiedeberg's Archives of Pharmacology | Springer Nature Link